Jupiter Neurosciences Inc JUNS

US Pharmaceuticals

$0.09 ▼ -7.69% ($-0.01)

🧊 52W Low ⬇️ Below Yest. Low

Open $0.09

Prev Close $0.10

Day Range $0.08 – $0.10

52W Range $0.08 – $1.84

Market Cap $4.34M

Beta 1.69

EPS (TTM) $-0.26

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-12-03
Shares Out.	56,520,000
Website	jupiterneurosciences.com/ ↗
Phone	15614066154
Employees	5
Revenue	$18,652
Gross Profit	$14,290
Net Income	-$2.1M
Total Assets	$3.9M
Total Liabilities	$6.7M
Equity	-$2.8M

About Jupiter Neurosciences Inc

Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Jupiter Neurosciences Inc is a publicly traded company under the ticker symbol JUNS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.